ScholarLens Back to search
2008•The Journal of Clinical PsychiatryRequires access

Clinical study of aripiprzole in treatment of hyperprolactinemia caused by risperidone

Zhan-kui Cai

Open publisher page 0 citations

Abstract

Objective: To explore the efficacy and tolerability of aripiprazole in the treatment of hyperprolactinemia caused by risperidone. Method:Sixty schizophrenic patients with hyperprolactinemia associated with risperidone were randomly divided into aripiprazole group(n=30)and placebo group(n=30),receiving 6 weeks treatment .The prelactin (PRL) was measured at the baseline and the end of study.The efficacy and side effects were assessed with the brief psychiatric rating scale (BPRS) and the treatment emergent symptom scale (TESS) before and after treatment. Results:The concentration of PRL decreased significantly in aripiprazole group after treatment (P0.001).Disappearance of feminine-like breast presented in male patients (11/13)and spontaneous lactation(18/19)were observed in aripiprazole group.There were no significant differences before and after treatment in placebo group (P0.05). Conclusion: Aripiprazole is effective in the treatment of hyperprolactinemia caused by risperidone.

About this research paper

What this paper is about

Objective: To explore the efficacy and tolerability of aripiprazole in the treatment of hyperprolactinemia caused by risperidone. Method:Sixty schizophrenic patients with hyperprolactinemia associated with risperidone were randomly divided into aripiprazole group(n=30)and placebo group(n=30),receiving 6 weeks treatment .The prelactin (PRL) was measured at the baseline and the end of study.The efficacy and side effects were assessed with the brief psychiatric rating scale (BPRS) and the treatment emergent symptom scale (TESS) before and after treatment. Results:The concentration of PRL decreased significantly in aripiprazole group after treatment (P0.001).Disappearance of feminine-like breast presented in male patients (11/13)and spontaneous lactation(18/19)were observed in aripiprazole group.There were no significant differences before and after treatment in placebo group (P0.05). Conclusion: Aripiprazole is effective in the treatment of hyperprolactinemia caused by risperidone.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective: To explore the efficacy and tolerability of aripiprazole in the treatment of hyperprolactinemia caused by risperidone. Method:Sixty schizophrenic patients with hyperprolactinemia associated with risperidone were randomly divided into aripiprazole group(n=30)and placebo group(n=30),receiving 6 weeks treatment .The prelactin (PRL) was measured at the baseline and the end of study.The efficacy and side effects were assessed with the brief psychiatric rating scale (BPRS) and the treatment emergent symptom scale (TESS) before and after treatment. Results:The concentration of PRL decreased significantly in aripiprazole group after treatment (P0.001).Disappearance of feminine-like breast presented in male patients (11/13)and spontaneous lactation(18/19)were observed in aripiprazole group.There were no significant differences before and after treatment in placebo group (P0.05). Conclusion: Aripiprazole is effective in the treatment of hyperprolactinemia caused by risperidone.

Key concepts: Aripiprazole, Risperidone, Tolerability, Placebo, Psychology, Brief Psychiatric Rating Scale, Internal medicine, Rating scale

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical study of aripiprzole in treatment of hyperprolactinemia caused by risperidone — Research Paper | ScholarLens